Back to top

Protagonist Therapeutics announces presentations of icotrokinra data

Protagonist Therapeutics (PTGX) announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Invesco Financial Preferred ETF (PGF)

Protagonist Therapeutics, Inc. (PTGX)